§ 51.1. Overview.
236 words·~1 min read·
/us/cfr/t26/s§ 51.1·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)The regulations in this part 51 are designated “Branded Prescription Drug Fee Regulations.”
(b)The regulations in this part 51 provide guidance on the annual fee imposed on covered entities engaged in the business of manufacturing or importing branded prescription drugs by section 9008 of the Patient Protection and Affordable Care Act (ACA), Public Law 111-148 (124 Stat. 119 (2010)), as amended by section 1404 of the Health Care and Education Reconciliation Act of 2010 (HCERA), Public Law 111-152 (124 Stat. 1029 (2010)). All references in these regulations to section 9008 are references to section 9008 of the ACA, as amended by section 1404 of HCERA. Unless otherwise indicated, all other section references are to sections in the Internal Revenue Code. All references to “fee” in these regulations are references to the fee imposed by section 9008.
(c)Section 9008(b)(4) sets an applicable fee amount for each year, beginning with 2011, that will be apportioned among covered entities with aggregate branded prescription drug sales of over $5 million to government programs or pursuant to coverage under such programs. Generally, each covered entity is liable for a fee in each fee year that is based on its sales of branded prescription drugs in the sales year that corresponds to the fee year in an amount determined by the Internal Revenue Service
(IRS)under the rules of this part. [T.D. 9684, 79 FR 43639, July 28, 2014]
Connections1 cite this
Cited by 1 section
5 references not yet in our index
- Pub. L. 111-148
- 124 Stat. 119
- Pub. L. 111-152
- 124 Stat. 1029
- T.D. 9684
Citation graph
cites case law
§ 51.1
Overview.
Fed. Reg.×1
Pub. L.Pub. L. 111-148
Stat.124 Stat. 119
Pub. L.Pub. L. 111-152
Stat.124 Stat. 1029
Treas. Dec.T.D. 9684
Cites 5Cited by 1 across 1 source